Livforsakringsbolaget Skandia Omsesidigt Has $314,000 Stock Holdings in Agilent Technologies, Inc. (NYSE:A)

Livforsakringsbolaget Skandia Omsesidigt decreased its stake in Agilent Technologies, Inc. (NYSE:A) by 68.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,331 shares of the medical research company’s stock after selling 5,020 shares during the quarter. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Agilent Technologies were worth $314,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of A. McAdam LLC raised its position in Agilent Technologies by 3.1% during the third quarter. McAdam LLC now owns 2,531 shares of the medical research company’s stock valued at $376,000 after buying an additional 77 shares during the period. Brown Brothers Harriman & Co. lifted its position in shares of Agilent Technologies by 13.5% in the third quarter. Brown Brothers Harriman & Co. now owns 646 shares of the medical research company’s stock worth $96,000 after purchasing an additional 77 shares in the last quarter. Global Retirement Partners LLC boosted its holdings in shares of Agilent Technologies by 3.2% during the third quarter. Global Retirement Partners LLC now owns 2,570 shares of the medical research company’s stock worth $382,000 after purchasing an additional 79 shares during the period. Rovin Capital UT ADV increased its stake in Agilent Technologies by 1.6% in the 3rd quarter. Rovin Capital UT ADV now owns 5,049 shares of the medical research company’s stock valued at $750,000 after buying an additional 81 shares during the period. Finally, Marshall Financial Group LLC lifted its position in Agilent Technologies by 1.0% in the 3rd quarter. Marshall Financial Group LLC now owns 8,243 shares of the medical research company’s stock worth $1,224,000 after buying an additional 82 shares in the last quarter. Institutional investors and hedge funds own 87.42% of the company’s stock.

Agilent Technologies Stock Performance

Shares of A opened at $145.21 on Friday. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.09 and a quick ratio of 1.58. Agilent Technologies, Inc. has a one year low of $124.16 and a one year high of $155.35. The company’s fifty day moving average price is $141.44 and its 200 day moving average price is $139.19. The company has a market capitalization of $41.43 billion, a PE ratio of 32.85, a price-to-earnings-growth ratio of 4.10 and a beta of 1.07.

Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Monday, November 25th. The medical research company reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.41 by $0.05. The business had revenue of $1.70 billion during the quarter, compared to analysts’ expectations of $1.67 billion. Agilent Technologies had a return on equity of 25.43% and a net margin of 19.80%. The firm’s revenue was up .8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.38 EPS. As a group, analysts expect that Agilent Technologies, Inc. will post 5.56 earnings per share for the current year.

Agilent Technologies Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, January 22nd. Stockholders of record on Tuesday, December 31st were paid a $0.248 dividend. This is an increase from Agilent Technologies’s previous quarterly dividend of $0.24. The ex-dividend date was Tuesday, December 31st. This represents a $0.99 annualized dividend and a dividend yield of 0.68%. Agilent Technologies’s dividend payout ratio (DPR) is presently 22.40%.

Insider Buying and Selling

In related news, CEO Padraig Mcdonnell sold 1,911 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $150.00, for a total value of $286,650.00. Following the completion of the sale, the chief executive officer now owns 39,652 shares in the company, valued at approximately $5,947,800. This trade represents a 4.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.33% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A has been the topic of several research analyst reports. Bank of America lowered their price target on shares of Agilent Technologies from $153.00 to $150.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. JPMorgan Chase & Co. cut their price target on Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating for the company in a research note on Tuesday, November 26th. Wells Fargo & Company lowered their price target on Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating for the company in a research note on Monday, December 9th. Sanford C. Bernstein cut their price objective on shares of Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating on the stock in a research report on Tuesday, November 26th. Finally, Barclays decreased their target price on shares of Agilent Technologies from $145.00 to $135.00 and set an “underweight” rating for the company in a research report on Wednesday, November 27th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $143.62.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.